Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: The PROMETHEUS-01 trial

[1]  T. Umemura,et al.  Epidemiology of hepatocellular carcinoma in Japan , 2009, Journal of Gastroenterology.

[2]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[3]  M. Hebbar,et al.  Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma , 2008, Cancer.

[4]  Y. Akine,et al.  Proton beam therapy for aged patients with hepatocellular carcinoma. , 2007, International journal of radiation oncology, biology, physics.

[5]  Jeffrey W. Clark,et al.  Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma , 2007, Cancer.

[6]  Hirohiko Tsujii,et al.  Particle radiation therapy using proton and heavier ion beams. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  T. Hashimoto,et al.  Proton Beam Therapy for Hepatocellular Carcinoma Patients with Severe Cirrhosis , 2006, Strahlentherapie und Onkologie.

[8]  L. Wenjian,et al.  Correlation between initial chromatid damage and survival of various cell lines exposed to heavy charged particles , 2006, Radiation and environmental biophysics.

[9]  T. Hashimoto,et al.  Proton beam therapy for hepatocellular carcinoma with limited treatment options , 2006, Cancer.

[10]  L. Wenjian,et al.  Survival and initial chromatid breakage in normal and tumour cells exposed in vitro to gamma rays and carbon ions at the HIRFL. , 2006, The British journal of radiology.

[11]  J. Llovet,et al.  Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials , 2006, Alimentary pharmacology & therapeutics.

[12]  T. Hashimoto,et al.  Repeated proton beam therapy for hepatocellular carcinoma. , 2005, International journal of radiation oncology, biology, physics.

[13]  T. Hashimoto,et al.  Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus , 2005, Cancer.

[14]  K. Kagei,et al.  Proton Beam Therapy for Hepatocellular Carcinoma: A Retrospective Review of 162 Patients , 2005, Clinical Cancer Research.

[15]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[16]  Riwa Kishimoto,et al.  Overview of clinical experiences on carbon ion radiotherapy at NIRS. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  T. Obata,et al.  Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. , 2004, International journal of radiation oncology, biology, physics.

[18]  J. Furuse,et al.  A phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Lech Papiez,et al.  Extracranial Stereotactic Radiation Delivery: Expansion of Technology Beyond the Brain , 2003, Technology in cancer research & treatment.

[20]  J. Bruix,et al.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.

[21]  T. Gojobori,et al.  A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Miyazaki,et al.  Cholangiocarcinoma: Recent progress. Part 1: Epidemiology and etiology , 2002, Journal of gastroenterology and hepatology.

[23]  C. Suh,et al.  Dose-response relationship in local radiotherapy for hepatocellular carcinoma. , 2001, International journal of radiation oncology, biology, physics.

[24]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[25]  U Oppitz,et al.  Stereotactic radiotherapy of extracranial targets: CT-simulation and accuracy of treatment in the stereotactic body frame. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  R. T. Ten Haken,et al.  Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  F Lohr,et al.  Extracranial stereotactic radiation therapy: set-up accuracy of patients treated for liver metastases. , 2000, International journal of radiation oncology, biology, physics.

[28]  H. El‐Serag,et al.  Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.

[29]  M. Mondelli,et al.  Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study , 1997, Hepatology.

[30]  M. Kessler,et al.  Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers. , 1997, International journal of radiation oncology, biology, physics.

[31]  H. Blum.  Does hepatitis C virus cause hepatocellular carcinoma? , 1994, Hepatology.

[32]  M. Kessler,et al.  Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  H. Tsukuma,et al.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease. , 1993, The New England journal of medicine.

[34]  Morton B. Brown,et al.  The use of 3-D dose volume analysis to predict radiation hepatitis. , 1993, International journal of radiation oncology, biology, physics.

[35]  M. Colombo,et al.  Hepatocellular carcinoma in Italian patients with cirrhosis. , 1991, The New England journal of medicine.

[36]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[37]  M. Houghton,et al.  PREVALENCE OF ANTIBODIES TO HEPATITIS C VIRUS IN ITALIAN PATIENTS WITH HEPATOCELLULAR CARCINOMA , 1989, The Lancet.

[38]  J. Bruix,et al.  PREVALENCE OF ANTIBODIES TO HEPATITIS C VIRUS IN SPANISH PATIENTS WITH HEPATOCELLULAR CARCINOMA AND HEPATIC CIRRHOSIS , 1989, The Lancet.

[39]  A. Sonnenberg,et al.  Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. , 1985, The New England journal of medicine.

[40]  Williams Jt,et al.  ROYAL COLLEGE OF PHYSICIANS. THE NEW BUILDING. , 1964, Lancet.

[41]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[42]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[43]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[44]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[45]  I. Lax,et al.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. , 1995, Acta oncologica.

[46]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.